Optimize your patient outcomes
Our cutting-edge RNA sequencing technology and state-of-the-art artificial intelligence platform deliver personalized, preventative oral health solutions to dental professionals, empowering you to optimize patient outcomes.
An unhealthy oral microbiome can lead to chronic conditions
The oral microbiome has been the focus of intense research in recent years. As the entry point to your entire body, it is no surprise that in addition to mouth diseases, the oral microbiome has been implicated in many systemic diseases.
Problems with oral health caused by underlying, suboptimal microbial activities—such as cavities, gum disease, and tooth loss—can and do affect overall health. In recent years, science has linked the oral microbiome to many chronic diseases and health issues.
A Signal
in the Noise
The proprietary combination of Viome’s metatranscriptomic sequencing technology, our systems biology approach, and our AI machine learning platform is revolutionizing modern-day dentistry to improve the detection and outcomes for oral & throat cancers and other oral conditions that can impact overall health.
Our Unique Approach
Our precision solutions for dental professionals improve clinical outcomes by analyzing oral molecular data with artificial intelligence to identify specific biomarkers of oral conditions.
Metatranscriptomic Technology
(RNA Analysis)
Microbial and human gene expression are redefining how biological activities are viewed in relation to human health. Viome's metatranscriptomic technology is the only clinically validated metatranscriptomic technology in the world.
DNA
RNA plays a fundamental role in human biology referring the instructions stored in DNA to make the proteins required in every living cell. Our approach is to use RNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease.
RNA
Oral Pro Health Scores
Unlike other tests that focus on composition, our RNA sequencing technology enables us to measure the molecular activity of the oral microbiome and human cells in your patient’s mouth and identify early biomarkers of periodontitis disease, caries, gum inflammation, and other risks of oral and systemic diseases. With these scores, you can monitor the underlying signals of poor oral health and disease over time, and take action with a personalized treatment plan that addresses your patient’s unique needs.
CancerDetect®
Oral & Throat
Our CancerDetect®- Oral & Throat test was developed over multiple years by Viome Life Sciences, Inc, based on clinical studies for diagnostic development and validation. This test is a non-invasive, at-home test that detects a molecular signature associated with Oral and/or Throat cancers with high accuracy.
Viome’s commercially available CancerDetect Oral and Throat cancer test is a laboratory-developed test (LDT). This test was clinically validated with an independent cohort, with a specificity of at least 95% and a sensitivity of at least 90% for both Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal Squamous Cell Carcinoma (OPSCC). This surpasses the current standard of care - the visual and tactile exam.
Our Approach to Cancer Diagnostics
Step 1
Carefully define the disease and non-disease cohorts based on all available clinical meta-data.
Step 2
Systematically analyze those cohorts to identify a molecular signature, typically consisting of both human and microbial molecular features, that distinguishes the disease cohort from the non-disease cohort.
Step 3
Validate the discovered molecular signature using an unseen independent cohort that includes clinically adjudicated meta-data.
VIOME STUDY INITIATIVES
Cancer Research
In addition to head and neck cancers, Viome has an extensive ongoing clinical study pipeline in gastrointestinal cancers including colorectal cancer, pancreatic, ovarian, cervical, and biliary cancers. We currently have cancer research trials that use saliva, blood, stool, and tumor biopsies to understand the onset and progression of cancer. By identifying the biomarkers that lead to the development of cancers, Viome can optimize early detection and identify the right therapeutic targets.
Publications
The salivary metatranscriptome as an accurate diagnostic indicator of oral cancer.
NPJ Genomic Medicine (Nature Press)
Partners
Viome is for everyone, no matter where you are in your health journey. Here you can learn more about what our tests and supplement plan options can do for you, by discovering some of our many customer testimonials. Join over 400,000 people taking control of their health with Viome. Because your body is unique, and your diet should be to
Work With Us
Our Grants Program
The mission of the VLS Grants Program is to enable clinicians and scientists worldwide to translate research into commercial products with clinical utility: devising new therapies and developing more accurate diagnostics and companion diagnostics.
Viome Publication Dataset Access Program
Viome is committed to supporting scientific research by enabling access to data we have included in our publications. We provide access to full summary statistics through a Data Transfer Agreement that protects the privacy of our participant's data.
Our Mission
We founded Viome Life Sciences with one goal in mind: to tackle the epidemic of chronic diseases, cancer, and aging and empower people with the information they need to live a disease-free life.
General inquiries
Partner with us